With the global COVID-19 count topping 40 million, amid the latest surge in the European coronavirus cases, Spanish pharmaceutical company PharmaMar came out with a piece of welcome news, citing that its cancer drug - Aplidin is enormously promising in treating COVID-19.
This comes after the Spanish pharma giant said Friday, a clinical trial of its cancer drug Aplidin to treat adult patients with COVID-19 was successful and it now aims to start phase III trials.
The statement read: "With these data, the company will begin, in the next few days, conversations with the regulatory agencies to define the next phase III pivotal study for plitidepsin (Aplidin) in patients with COVID-19, who require hospitalization."
Note that the drug is approved in Australia for the treatment of multiple myeloma.
S&P 500 futures rebound to 3,500
Amid encouraging vaccine news and upbeat European earnings reports, the sentiment remains lifted and helps boost the recovery in the S&P 500 futures.
The futures tied to the S&P 500 index rallies 0.88% to trade at 3,493, recovering from Friday’s low of 3,461.25.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD consolidates weekly gains below 1.0900 ahead of NFP
EUR/USD stays in a consolidation phase and trades below 1.0900 in the European session on Friday. Investors move to the sidelines while waiting for the US October employment report, which will highlight Nonfarm Payrolls and Unemployment Rate figures.
GBP/USD stabilizes near 1.2900, eyes on US employment report
GBP/USD holds steady at around 1.2900 early Friday after closing deep in the red on Thursday. Despite the persistent USD weakness, the risk-averse market atmosphere didn't allow the pair to gain traction. Investors await US NFP data.
Gold recovers above $2,750 as traders brace for US NFP data
Gold recovers some lost ground and trades above $2,750 on Friday. The uncertainties surrounding the US presidential election and the ongoing geopolitical tensions in the Middle East provide some support to the precious metal, a traditional safe-haven asset.
US Nonfarm Payrolls Forecast: NFP October report set to show slower job growth
US Nonfarm Payrolls are expected to rise by 113K in October after September’s stellar gain of 254K. The United States Bureau of Labor Statistics will release the labor data on Friday at 12:30 GMT. The US Dollar’s fate and the Fed’s future interest rate cuts hinge on the US jobs data.
Bank of Japan holds rates steady amid signs of modest GDP growth
Monthly industrial production results have been mixed but generally indicate a modest recovery in third-quarter GDP. Clear guidance from the Bank of Japan remains elusive, with each upcoming meeting being pivotal.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.